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followed by DTIC q3w × 4 and then IPI every 12 weeks 
until disease progression or intolerable toxicity.
Results All 15 treated patients reported drug-related AEs, 
the most common of which were increases in alanine ami-
notransferase (n = 12, 80 %) and aspartate aminotrans-
ferase (n = 11, 73 %). Treatment-related serious AEs were 
reported in 11 (73 %) patients. Nine patients (60 %) dis-
continued treatment due to drug-related toxicities. Immune-
related AEs (irAEs) were reported in 14 patients (93 %). 
The most frequent irAEs were liver (n = 12, 80 %) and 
skin (n = 10, 67 %) toxicities. Five deaths were reported; 
all were caused by progressive disease. Efficacy evalua-
tion showed one complete response, one partial response 
and four patients with stable disease. Best overall response 
rate was 13 % (2/15), and the disease control rate was 40 % 
(6/15). The study was terminated early due to frequent, 
high-grade liver toxicities.
Conclusions IPI 10 mg/kg plus DTIC 850 mg/m2 was not 
considered tolerable in the Japanese patient population.
ClinicalTrials.gov identifier: NCT01681212.
Keywords Ipilimumab · Dacarbazine · Immune-
checkpoint inhibitor · Melanoma · Phase 2 study · Japanese 
patients
Introduction
Ipilimumab (IPI), a fully human IgG1 monoclonal anti-
body, is an antagonist to an immune-checkpoint receptor, 
cytotoxic T lymphocyte antigen-4 (CTLA-4), which down-
regulates antitumor T cell function [1, 2]. Blockade of 
CTLA-4 has been shown to increase effector T cell activa-
tion, proliferation and infiltration into tumors and to inhibit 
Abstract 
Purpose Ipilimumab (IPI), a monoclonal antibody against 
immune-checkpoint receptor cytotoxic T lymphocyte anti-
gen-4, is designed to enhance antitumor T cell function. IPI 
10 mg/kg plus dacarbazine (DTIC) significantly improved 
overall survival in a phase 3 study involving predominantly 
Caucasian patients, with an adverse event (AE) profile sim-
ilar to that of IPI monotherapy. We conducted a single-arm, 
phase 2 study to evaluate the safety and efficacy of IPI plus 
DTIC in Japanese patients.
Methods Previously untreated patients with unresect-
able stage III or IV melanoma received IPI 10 mg/kg plus 
DTIC 850 mg/m2 every 3 weeks for four doses (q3w × 4), 
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immunosuppressive T regulatory cell function and prolif-
eration in tumor lesions [3–5].
IPI at a dose of 3 mg/kg has been approved by regula-
tory agencies in over 40 countries, including the USA [6] 
and recently in Japan, for the treatment of advanced (unre-
sectable or metastatic) melanoma. A phase 3 study of pre-
viously treated patients with advanced melanoma showed 
significantly improved overall survival (OS) with IPI 3 mg/
kg alone or IPI combined with gp100 compared to gp100 
alone [7]. A small, open-label, phase 2 study of IPI 3 mg/
kg monotherapy in Japanese patients with advanced mela-
noma showed similar safety and efficacy results as the tri-
als of mostly Caucasian patients [8]. Results were simi-
lar in a phase 1 study of Japanese patients with advanced 
non-small cell lung cancer treated with IPI combined with 
paclitaxel/carboplatin [9]. Adverse events (AEs) with IPI 
were frequently immune-related, consistent with the drug’s 
mechanism of action. Management guidelines for immune-
related AEs (irAEs) are available [10].
A pooled analysis of 10 prospective and 2 retrospective 
trials of IPI 3 or 10 mg/kg in advanced melanoma showed 
a 3-year survival rate of 22 % and a plateau in the survival 
curve beginning at approximately 3 years, with a follow-up 
to 10 years [11]. The pooled trials included patients receiv-
ing IPI monotherapy and those receiving combination ther-
apies. One of the trials was a phase 3 study (CA184-024) 
of patients with untreated, advanced melanoma receiving 
either IPI 10 mg/kg plus dacarbazine (DTIC) 850 mg/m2 
or DTIC plus placebo [12]. In that study, IPI plus DTIC 
resulted in a statistically significant improvement in OS 
compared with DTIC plus placebo. AEs were generally 
consistent with those seen in prior phase 2 studies of IPI 
monotherapy at a dose of 10 mg/kg [13–16]. However, the 
rates of Grade 3/4 hepatic events were higher [elevated ala-
nine aminotransferase (ALT) level, 22 % in study CA184-
024 versus 8 % in previous studies; elevated aspartate ami-
notransferase (AST) level, 18 % vs. 7 %], and the rates of 
Grade 3 or 4 gastrointestinal (GI) events were lower (rate 
of diarrhea, 4 % vs. 11 %; rate of colitis, 2 % vs. 5 %) than 
expected based on prior studies. The current study CA184-
202 investigated the safety and efficacy of IPI 10 mg/kg 




The study recruited previously untreated Japanese patients 
with histologic diagnosis of stage III or IV melanoma 
according to TNM staging classification [17]. Prior adju-
vant melanoma therapy was permitted. Key inclusion 
criteria were: life expectancy of ≥16 weeks; Eastern Coop-
erative Oncology Group (ECOG) performance status of 0 
or 1; adequate liver, renal and bone marrow function by 
specified parameters; and age ≥20 years. Key exclusion 
criteria were: evidence of brain metastases; other malig-
nancy within 5 years; history of or current active autoim-
mune disease; history of or concurrent GI perforations; 
human immunodeficiency virus, active hepatitis B, active 
hepatitis C or human T lymphotropic virus type 1 infection. 
Prohibited therapies included: prior use of any anticancer 
agent for melanoma, prior adjuvant therapy within 4 weeks 
of study drug administration, concomitant use of immuno-
suppressive agents or prior use of immunotherapy drugs, 
such as CTLA-4 inhibitors.
Study oversight
This study was sponsored by Bristol-Myers Squibb. The 
study protocol was approved by the Institutional Review 
Board at each study site, and research was conducted in 
accordance with the standards specified by Article 14 Par-
agraph 3 and Article 80-2 of the Pharmaceutical Affairs 
Law, and Good Clinical Practice, as defined by the Minis-
terial Ordinance Concerning the Standards for the Imple-
mentation of Clinical Studies on Pharmaceutical Products 
and concerning notifications, and in accordance with ethi-
cal principles underlying the Declaration of Helsinki. All 
study participants provided written, informed consent prior 
to enrollment.
Study design and treatment
This was an open-label, single-arm, phase 2 study in pre-
viously untreated patients with unresectable or metastatic 
melanoma (ClinicalTrials.gov, NCT01681212) (Fig. 1). 
After screening for eligibility, patients entered the induc-
tion phase in which they received concomitant IPI 10 mg/
kg and DTIC 850 mg/m2 every 3 weeks for four doses, 
both starting at week 1 (day 1), followed by 4 treatments 
of DTIC alone every 3 weeks. In the maintenance phase, 
patients without progressive disease who continued to 
tolerate treatment were administered IPI 10 mg/kg alone 
every 12 weeks. Tumor assessments were performed at 
weeks 12, 16, 20 and 24 during induction. During mainte-
nance, tumor assessments were performed every 6 weeks 
until week 48 and then every 12 weeks until disease pro-
gression. Follow-up phases monitored toxicity, progres-
sive disease and OS. Patients were followed for AEs for 
a minimum of 90 days following the last dose of IPI or 
for 30 days following the last dose of DTIC, whichever 
occurred later. AE assessments continued until all AEs 
were resolved, had returned to baseline or were deemed 
irreversible or stable.
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Study endpoints and assessments
The primary endpoint was survival rate at 1 year. The 
secondary endpoint was frequency of Grade 3/4 irAEs, 
reported in the following organ categories: GI, liver, 
skin, endocrine, neurological and other. irAEs were 
defined as drug-related and in a specified list from the 
most recent Medical Dictionary for Regulatory Activi-
ties (MedDRA) group terms and preferred terms. Toxic-
ity management guidelines were provided by the sponsor 
(Supplemental Fig. 1) and have been published previ-
ously [10]. Exploratory endpoints included safety, OS, 
best overall response rate (BORR), progression-free 
survival (PFS), duration of response (DOR) and disease 
control rate (DCR).
Safety assessments were performed prior to study drug 
dosing, in addition to assessments made as part of the 
standard of care. Safety was evaluated using the National 
Cancer Institute Common Terminology Criteria for Adverse 
Events version 3.0. Response-based endpoints were cap-
tured using modified World Health Organization Criteria. 
Tumor assessment by computed tomography (CT) or mag-
netic resonance imaging (MRI) was required at screening; 
response was documented by CT or MRI methods similar 
to those used at screening.
Statistical methods
Survival rate at 1 year was calculated from the number of 
patients alive at 1 year following the first dose of study 
therapy divided by the total number of patients treated, 
with a corresponding 2-sided 90 % confidence interval 
(CI). BORR and DCR were calculated with correspond-
ing 2-sided 95 % CIs. Safety was evaluated in all treated 
patients. The study was designed so that with 26 patients 
there was an 80 % power to reject the null hypothesis that 
the true 1-year survival rate was ≤25 %.
Results
Patients, treatment and disposition
A total of 21 patients with advanced melanoma were 
enrolled in the study; 15 patients were treated with 
study drug [untreated patients either no longer met study 
inclusion criteria (n = 5) or were not treated due to 
administrative reasons (n = 1)]. Table 1 shows patient 
demographics. Most patients had M1b or M1c stage 
melanoma at screening, an ECOG performance status of 
0 and normal lactate dehydrogenase levels. The majority 
of patients (60 %) had received prior adjuvant therapy. 
Most patients had normal baseline hematology results 
(≥73 %), liver function tests (≥93 %), renal func-
tion (creatinine, ≥93 %) and serum amylase and lipase 
(≥86 %).
A total of 6 (40 %) patients received all four doses of 
IPI during the induction phase. Nine patients discontinued 
treatment prior to the fourth dose due to study drug tox-
icity or disease progression (n = 4 received three doses, 
n = 5 received two doses). The median number of doses 
per patient in the induction phase was 3 (range 2–4). Two 
patients (13 %) received all eight doses of DTIC dur-
ing induction. Two patients were dosed in the mainte-
nance phase, receiving one dose and three doses of IPI, 
respectively.
All 15 patients were off treatment at the conclusion of 
the study. Drug-related toxicity was the most common rea-
son for study drug discontinuation [nine patients (60 %)]. 
Eight patients (53 %) discontinued due to elevations in 
Screening
Induction Phase Maintenance Phase Follow-up Phase
(Toxicity and Survival)
For patients with PD, drug 
intolerance or who no longer 
consent to treatment
TA schedule Baseline Follow-up PhaseTA continued until PD 
Maintenance Phase
q6w to W48, then q12w until PD
Induction Phase




W13, 16, 19, 22
IPI + DTIC, q3w 
W1, 4, 7, 10
Fig. 1  Schema showing 5 phases of study CA184-202 and the tumor assessment schedule. DTIC dacarbazine; IPI ipilimumab; PD progressive 
disease; q3w every 3 weeks; q6w every 6 weeks; q12w every 12 weeks; TA tumor assessment; W week
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serum ALT or AST levels. Five patients (33 %) discontin-
ued due to disease progression, and one patient (7 %) had 
reached the maximum clinical benefit. The study was ter-
minated early due to a high frequency of Grade 3/4 liver 
function test abnormalities following administration of IPI 
in combination with DTIC.
Safety
Safety results are summarized in Table 2. A total of 14 
(93 %) patients reported a serious adverse event (SAE) of 
any grade. There were 11 (73 %) patients with SAEs that 
were considered by the investigator to be drug-related 
(Grade 2–4 ALT and AST increases, Grade 2 colitis, Grade 
3 diarrhea and Grade 1 dizziness) (Table 3). There were 
five deaths in this study, all of which were due to progres-
sive disease, and all occurred more than 90 days after the 
last dose of study drug.
All 15 subjects in this study reported at least 1 drug-
related AE (Table 2). Nine (60 %) patients discontin-
ued from the study due to drug-related Grade 2–3 AEs 
(Grade 3 ALT, AST increases; Grade 2 AST increase and 
Grade 2 colitis). The most common drug-related AE of 
any grade was ALT increase in 12 patients (80 %). There 
was 1 drug-related Grade 4 AE of elevation in ALT in 1 
(6.7 %) patient, and there were no drug-related Grade 5 
AEs.
The majority of drug-related AEs were immune-related. 
Grade 3/4 irAEs were reported in 11 (73 %) patients 
(Table 2). The most commonly reported irAEs were liver 
events (ALT increase and/or AST increase) in 12 patients 
(80 %). Eleven patients (73 %) experienced liver irAEs that 
were Grade 3 or 4 in severity. Skin irAEs were reported in 
10 (67 %) patients, and GI irAEs were reported in 6 (40 %) 
patients. There were no GI perforations. Endocrine irAEs 
were reported in 3 (20 %) patients (n = 2 with Grade 2 
hypothyroidism and n = 1 with Grade 2 hypophysitis). 
There were no neurological irAEs and no Grade 5 irAEs.
All patients who had irAEs (n = 14, 93 %) in this study 
were treated with symptomatic therapies, steroids and/or 
other immunosuppressive therapies for irAE management. 
All 14 patients were treated with corticosteroids. Nine 
patients were treated with immunosuppressive therapies. 
Eight patients received mycophenolic acid for liver toxic-
ity, and one patient was treated with infliximab for diarrhea 
and colitis. All but 2 irAEs of ≥Grade 2 resolved to Grade 
1 or less. Two patients with endocrine irAEs (hypophysitis 
or hypothyroidism) were unresolved, with continuation of 
hormone replacement therapy (L-thyroxine and levothy-
roxine) at study termination. A post-study irAE of autoim-
mune thyroiditis in the same patient with hypophysitis also 
remained ongoing, and treatment with L-thyroxine was 
continued. Time to onset of ≥Grade 2 irAEs ranged from 
0.1 week (GI irAE) to 23 weeks (endocrine irAE) after ini-
tiation of study therapy. Among those that resolved, time 
to resolution ranged from 0.4 weeks (n = 3 GI irAEs) to 
30 weeks (GI irAE).
Efficacy
The primary endpoint of survival rate at 1 year could not 
be evaluated because the study was terminated early due to 
severe liver toxicity. However, survival rate at 1 year was 
observed to be 67 % (90 % CI 42.3, 85.8) at final data-
base lock (Table 4). With one patient having a complete 
response that was ongoing at last contact and one patient 
achieving a partial response, the best overall response rate 
was 13 % (n = 2/15, 95 % CI 1.7, 40.5). Four additional 
patients had stable disease, making the disease control rate 
40 % (n = 6/15, 95 % CI 16.3, 67.7) (Table 4).
Discussion
This open-label, phase 2 study of IPI 10 mg/kg plus DTIC 
850 mg/m2 in previously untreated Japanese patients with 
advanced melanoma was terminated early due to severe 
liver toxicity. Eleven out of 15 patients (73 %) had Grade 
3/4 liver function test elevations considered to be immune-
related, and 8 treatment discontinuations were due to 
Table 1  Patient demographics
ECOG Eastern Cooperative Oncology Group, LDH lactate dehydro-
genase, ULN upper limit of normal
Characteristic Treated patients (N = 15)
Gender, n (%)
 Male 10 (66.7)
Race, n (%)
 Japanese 15 (100)
Age, years
 Median (range) 61 (36–70)
M stage at entry, n (%)
 M0 1 (6.7)
 M1a 0 (0)
 M1b 7 (46.7)
 M1c 7 (46.7)
ECOG performance status
 0 13 (86.7)
 1 2 (13.3)
Baseline LDH > ULN, n (%)
 Normal 12 (80)
 Elevated 3 (20)
Prior adjuvant therapy
 Yes 9 (60)
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elevations in ALT or AST. Other than hepatotoxicity, the 
safety profile in this trial was similar to previous experience 
with IPI. There were not enough patients to evaluate the 
primary efficacy endpoint. However, the observed survival 
rate at 1 year was 67 %.
In a phase 3 trial of approximately 500 previously 
untreated mostly Caucasian patients receiving IPI plus DTIC 
(in a similar treatment regimen to that of the present study) or 
DTIC plus placebo, the estimated survival rate with IPI plus 
DTIC was significantly greater than the rate with DTIC plus 
placebo at years 1 through 3 and at year 5 [12, 18]. How-
ever, the rates of immune-related Grade 3/4 elevations in 
ALT (21 %) and AST (17 %) reported in that study [12] were 
higher than Grade 3/4 hepatic irAEs previously reported in 
mostly Caucasian patients receiving IPI monotherapy at 3 or 
10 mg/kg (0–12 %) [7, 15, 19]. The current study suggests 
that the risk of hepatic toxicity in Japanese patients is con-
siderably higher. In a phase 1 trial of Japanese patients with 
non-small cell lung cancer, IPI 10 mg/kg in phased combina-
tion with paclitaxel and carboplatin was tolerable [20].
DTIC monotherapy is associated with hepatotoxicity 
[21–23], and the hepatotoxicity reported in the current study 
could have been due to the combination of IPI with DTIC. In 
a phase 2 study (CA184-396) of IPI 3 mg/kg monotherapy 
in Japanese patients, immune-related Grade 3 elevations in 
Table 2  Safety results summary
AEs adverse events, ALT alanine aminotransferase, AST aspartate 
aminotransferase, irAEs immune-related adverse events, SAEs serious 
adverse events
Event Treated patients (N = 15)
AEs
 Grade 3/4 AEs 15 (100)
 Drug-related AEs 15 (100)
  Drug-related Grade 3/4 AEs 11 (73.3)
 Most frequent AEs (occurring in ≥ 20 % of patients)
  ALT increased 12 (80)
  AST increased 11 (73.3)
  Constipation 8 (53.3)
  Nausea 7 (46.7)
  Rash 6 (40)
  Diarrhea 5 (33.3)
  Weight decreased 4 (26.7)
  Back pain 4 (26.7)
  Pyrexia 4 (26.7)
  Decreased appetite 3 (20)
  Diabetes mellitus 3 (20)
  Hyperglycemia 3 (20)
  Malignant neoplasm progression 3 (20)
irAEs
 Grade 3/4 irAEs 11 (73.3)
 Skin irAEs 10 (66.7)
 Liver irAEs 12 (80)
 Gastrointestinal irAEs 6 (40)
 Endocrine irAEs 3 (20)
 Neurological irAEs 0 (0)
 Other irAEs 2 (13.3)
SAEs 14 (93.3)
 Drug-related SAEs 11 (73.3)
AEs leading to discontinuation of study 
therapy
9 (60)
 Drug-related AEs leading to discontinu-
ation
9 (60)
Table 3  On-study drug-related SAEsa,b,c
ALT alanine aminotransferase, AST aspartate aminotransferase, SAE 
serious adverse event
a Patients may have had more than 1 event
b Drug-related events are those reported as related or missing
c On-study events are those reported between the first dose and 
90 days after the last dose date of study treatment
Organ categorya Treated patients (N = 15)
Worst grade, n (%)
Grade 1 Grade 2 Grade 3 Grade 4 Any grade
Any drug-related 
SAE
0 1 (6.7) 9 (60) 1 (6.7) 11 (73.3)
Investigations 0 0 9 (60) 1 (6.7) 10 (66.7)
  ALT increased 0 0 9 (60) 1 (6.7) 10 (66.7)
  AST increased 0 1 (6.7) 6 (40) 0 7 (46.7)
Gastrointestinal 
disorders
0 1 (6.7) 1 (6.7) 0 2 (13.3)
  Colitis 0 1 (6.7) 0 0 1 (6.7)
  Diarrhea 0 0 1 (6.7) 0 1 (6.7)
Nervous system 
disorders
1 (6.7) 0 0 0 1 (6.7)
  Dizziness 1 (6.7) 0 0 0 1 (6.7)
Table 4  Overall survival and best overall response
CI confidence interval
Variable Treated patients (N = 15)
Overall survival
 Survival rate at 1 year, n [% (90 % CI)] 10 [66.7 (42.3, 85.8)]
Best overall response
 Complete response, n (%) 1 (6.7)
 Partial response, n (%) 1 (6.7)
 Stable disease, n (%) 4 (26.7)
 Progressive disease, n (%) 9 (60.0)
 Best overall response rate, n  
[% (95 % CI)]
2 [13.3 (1.7, 40.5)]
 Disease control rate, n [% (95 % CI)] 6 [40 (16.3, 67.7)]
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ALT and AST each occurred in only 5 % of patients, with 
no Grade 4 irAEs of any kind [8]. However, a high incidence 
of hepatotoxicity was also reported in a US phase 1 study 
of IPI combined with the BRAF mutation-targeted therapy 
vemurafenib [24]. This study was also terminated early due 
to liver toxicity. As in the present study, all hepatic AEs were 
reversible with either discontinuation of the study drugs or 
administration of corticosteroids or other immunosuppres-
sant agents. Extensive global experience with IPI has ena-
bled the development of effective treatment guidelines for 
the management of irAEs (Supplementary Fig. 1) [6].
Combination therapy of another immune-checkpoint 
inhibitor, nivolumab (NIVO), with IPI (IPI 3 mg/kg plus 
NIVO 1 mg/kg, q3w for four doses followed by NIVO 
3 mg/kg q2w) demonstrated a significantly improved 
objective response rate compared with IPI therapy alone 
(61 % compared with 11 %, respectively) in BRAF wild-
type patients treated in the phase 2 study CA209-069 [25]. 
Median PFS was not reached with NIVO plus IPI and was 
4.4 months with IPI alone (hazard ratio 0.40; 95 % CI 
0.23, 0.68, p < 0.001). Treatment-related hepatic AEs of 
Grade 3–4 occurred in 15 % of the predominantly Cauca-
sian patients receiving the combination therapy. NIVO, 
approved in Japan for treatment of patients with advanced 
melanoma in the year 2014, is a fully human IgG4 mono-
clonal antibody against the programmed death-1 (PD-1) 
immune-checkpoint receptor, with a mechanism of action 
that is distinct from IPI [25].
In conclusion, in this study of Japanese patients with 
advanced melanoma, the incidence of severe liver toxicity 
was higher than experienced in other clinical studies. How-
ever, there were no new safety signals in Japanese patients 
in this study, and the overall safety profile was similar to 
prior experience, except for hepatotoxicity. IPI 10 mg/kg 
combined with DTIC 850 mg/m2 was not considered toler-
able in this Japanese patient population. Due to early ter-
mination of the study, efficacy conclusions could not be 
reached. The observed rate of survival at 1 year was 67 %.
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